Needham downgrades Biogen on slow growth of Alzheimer's drug
Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
Syndax Pharmaceuticals (SNDX) Gets a Buy from TD Cowen
TD Cowen analyst Phil Nadeau maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today. The company’s shares closed last ...
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Samsung Bioepis, Biogen Get European Commission Approval For Opuviz, A Biosimilar To Aflibercept
(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.
BioPharma Dive4d
Eisai wins over European regulators on Alzheimer’s drug Leqembi
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Le Lézard4d
PEGylated Proteins Market Set to Reach USD 19.1 Billion by 2031, Driven by Advancements in Drug Delivery: - Market Research Intellect
The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...